BACKGROUND AND PURPOSE: Late local recurrences and second primary breast cancers are increasingly common. Proton beam therapy (PBT) reirradiation (reRT) may allow safer delivery of a second definitive radiotherapy (RT) course. We analyzed outcomes of patients with recurrent or new primary breast cancer who underwent reRT. MATERIALS AND METHODS: In an IRB-approved retrospective study, patient/tumor characteristics, treatment parameters, outcomes, and toxicities were collected for all consecutive patients with recurrent or new primary non-metastatic breast cancer previously treated with breast or chest wall RT who underwent PBT reRT. RESULTS: Forty-six patients received reRT using uniform (70%) or pencil beam (30%) scanning PBT. Median first RT, reRT, and cumulative doses were 60 Gy (range 45-66 Gy), 50.4 Gy(RBE) (40-66.6 Gy(RBE)), and 110 Gy(RBE) (96.6-169.4 Gy(RBE)), respectively. Median follow-up was 21 months. There were no local or regional recurrences; 17% developed distant recurrence. Two-year DMFS and OS were 92.0% and 93.6%, respectively. Nine of 13 (69.2%) patients who underwent implant or flap reconstruction developed capsular contracture, 3 (23.1%) requiring surgical intervention. One (7.7%) patient developed grade 3 breast pain requiring mastectomy after breast conserving surgery. No acute or late grade 4-5 toxicities were seen. Increased body mass index (BMI) was protective of grade ≥ 2 acute toxicity (OR = 0.84, 95%CI = 0.70-1.00). CONCLUSION: In the largest series to date of PBT reRT for breast cancer recurrence or new primary after prior definitive breast or chest wall RT, excellent locoregional control and few high-grade toxicities were encountered. PBT reRT may provide a relatively safe and highly effective salvage option. Additional patients and follow-up are needed to correlate composite normal tissue doses with toxicities and assess long-term outcomes.
BACKGROUND AND PURPOSE: Late local recurrences and second primary breast cancers are increasingly common. Proton beam therapy (PBT) reirradiation (reRT) may allow safer delivery of a second definitive radiotherapy (RT) course. We analyzed outcomes of patients with recurrent or new primary breast cancer who underwent reRT. MATERIALS AND METHODS: In an IRB-approved retrospective study, patient/tumor characteristics, treatment parameters, outcomes, and toxicities were collected for all consecutive patients with recurrent or new primary non-metastatic breast cancer previously treated with breast or chest wall RT who underwent PBT reRT. RESULTS: Forty-six patients received reRT using uniform (70%) or pencil beam (30%) scanning PBT. Median first RT, reRT, and cumulative doses were 60 Gy (range 45-66 Gy), 50.4 Gy(RBE) (40-66.6 Gy(RBE)), and 110 Gy(RBE) (96.6-169.4 Gy(RBE)), respectively. Median follow-up was 21 months. There were no local or regional recurrences; 17% developed distant recurrence. Two-year DMFS and OS were 92.0% and 93.6%, respectively. Nine of 13 (69.2%) patients who underwent implant or flap reconstruction developed capsular contracture, 3 (23.1%) requiring surgical intervention. One (7.7%) patient developed grade 3 breast pain requiring mastectomy after breast conserving surgery. No acute or late grade 4-5 toxicities were seen. Increased body mass index (BMI) was protective of grade ≥ 2 acute toxicity (OR = 0.84, 95%CI = 0.70-1.00). CONCLUSION: In the largest series to date of PBT reRT for breast cancer recurrence or new primary after prior definitive breast or chest wall RT, excellent locoregional control and few high-grade toxicities were encountered. PBT reRT may provide a relatively safe and highly effective salvage option. Additional patients and follow-up are needed to correlate composite normal tissue doses with toxicities and assess long-term outcomes.
Authors: Barbara Fowble; Catherine Park; Frederick Wang; Anne Peled; Michael Alvarado; Cheryl Ewing; Laura Esserman; Robert Foster; Hani Sbitany; Alex Hanlon Journal: Int J Radiat Oncol Biol Phys Date: 2015-04-28 Impact factor: 7.038
Authors: Cristina M DeCesaris; Stephanie R Rice; Soren M Bentzen; Jenna Jatczak; Mark V Mishra; Elizabeth M Nichols Journal: Int J Radiat Oncol Biol Phys Date: 2019-04-24 Impact factor: 7.038
Authors: Harald Paganetti; Andrzej Niemierko; Marek Ancukiewicz; Leo E Gerweck; Michael Goitein; Jay S Loeffler; Herman D Suit Journal: Int J Radiat Oncol Biol Phys Date: 2002-06-01 Impact factor: 7.038
Authors: A C Voogd; G van Tienhoven; H L Peterse; M A Crommelin; E J Rutgers; C J van de Velde; B N van Geel; A Slot; P T Rodrigus; J J Jobsen; M F von Meyenfeldt; J W Coebergh Journal: Cancer Date: 1999-01-15 Impact factor: 6.860
Authors: Gary M Freedman; Penny R Anderson; Jinsheng Li; Debra F Eisenberg; Alexandra L Hanlon; Lu Wang; Nicos Nicolaou Journal: Am J Clin Oncol Date: 2006-02 Impact factor: 2.339
Authors: Prashant Gabani; Hetal Patel; Maria A Thomas; Beth Bottani; S Murty Goddu; William Straube; Julie A Margenthaler; Laura Ochoa; Jeff D Bradley; Imran Zoberi Journal: Clin Transl Radiat Oncol Date: 2019-10-02
Authors: P McGale; C Taylor; C Correa; D Cutter; F Duane; M Ewertz; R Gray; G Mannu; R Peto; T Whelan; Y Wang; Z Wang; S Darby Journal: Lancet Date: 2014-03-19 Impact factor: 79.321